Arvinas to Unveil Phase 1 Safety and PK/PD Data for PROTAC ARV-102
Arvinas will present Phase 1 safety, pharmacokinetic and pharmacodynamic data from its orally bioavailable PROTAC degrader ARV-102 targeting LRRK2 in Parkinson’s patients on March 18 at AD/PD™ 2026. The company plans to initiate a Phase 1b trial of ARV-102 in progressive supranuclear palsy in H1 2026 pending regulatory feedback.
1. Presentation Details
Arvinas will present data on multiple ascending doses of ARV-102 in participants with Parkinson’s disease during a dedicated symposium at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders on March 18 in Copenhagen, covering safety, pharmacokinetics and pharmacodynamics.
2. Phase 1 Trial Highlights
The ongoing Phase 1 study evaluates ARV-102’s ability to cross the blood-brain barrier and degrade LRRK2 in Parkinson’s patients, with preliminary assessments of tolerability, drug exposure levels and target engagement informing dose selection and future clinical strategy.
3. Next Steps for ARV-102
Pending regulatory feedback, Arvinas plans to initiate a Phase 1b trial of ARV-102 in patients with progressive supranuclear palsy in the first half of 2026, advancing its PROTAC platform into additional neurodegenerative indications.